cyclodextrin
sinc
discoveri
late
centuri
mainli
regard
excipi
nevertheless
develop
cyclodextrin
research
shown
host
captur
includ
biomolecul
highlight
fatti
acid
cholesterol
impli
inert
action
may
use
specif
medicin
purpos
present
review
center
literatur
report
year
present
day
present
comprehens
descript
known
biolog
activ
cyclodextrin
implic
medicin
applic
paper
divid
two
main
section
one
devot
properti
applic
cyclodextrin
activ
pharmaceut
ingredi
varieti
patholog
infecti
ailment
cardiovascular
dysfunct
metabol
diseas
second
section
dedic
use
cyclodextrin
rang
biomed
technolog
cyclodextrin
cd
first
report
villier
complet
anniversari
describ
villier
carbohydr
precipit
slowli
amidst
ferment
product
starch
form
beauti
radiant
crystal
figur
molecul
kept
much
attract
mysteri
first
five
decad
follow
discoveri
figur
crystal
complex
smallsiz
guest
phydroxybenzaldehyd
illustr
bright
cyclodextrin
crystal
first
describ
villier
earli
year
knowledg
human
cyclodextrin
subject
intens
scientif
curios
scientist
differ
group
sought
understand
origin
format
reactiv
includ
abil
host
molecul
importantli
figur
crystal
complex
smallsiz
guest
phydroxybenzaldehyd
illustr
bright
cyclodextrin
crystal
first
describ
villier
earli
year
knowledg
human
cyclodextrin
subject
intens
scientif
curios
scientist
differ
group
sought
understand
origin
format
biomolecul
wwwmdpicomjournalbiomolecul
reactiv
includ
abil
host
molecul
importantli
structur
cyclic
natur
cyclodextrin
postul
howev
first
propos
base
model
alon
also
erron
defin
smallest
cyclodextrina
five
glucos
unit
adequ
purif
crystal
structur
resolut
nativ
cyclodextrin
composit
accur
defin
six
seven
eight
glucos
unit
second
half
centuri
structur
properti
cyclodextrin
becam
known
greater
detail
studi
direct
toward
explor
abil
form
inclus
complex
variou
molecul
cyclodextrin
found
protect
sensit
organ
guest
molecul
volatil
oxid
solubil
action
apolar
guest
made
attract
varieti
applic
industri
product
cyclodextrin
start
make
avail
larger
quantiti
toxicolog
safeti
ascertain
detail
section
applic
pharmaceut
cosmet
food
chemistri
blossom
recent
applic
expand
emerg
area
nutraceut
natur
product
product
cyclodextrin
essenti
regard
excipi
inert
materi
turn
new
millennium
develop
cyclodextrin
biomed
research
surpris
scientif
commun
demonstr
molecul
quit
inert
may
fact
use
treat
human
ailment
medicin
properti
main
topic
review
present
detail
section
nativ
cd
regard
japan
natur
product
reason
use
without
mani
restrict
medicin
food
western
countri
ingest
nativ
cyclodextrin
regul
jecfa
joint
whofao
expert
committe
food
addit
pharmaceut
applic
fall
european
medicin
agenc
ema
europ
food
drug
administr
unit
state
america
nativ
cd
ingest
without
signific
absorpt
thu
gener
regard
safe
fda
commonli
refer
molecul
gra
statu
taken
without
restrict
oral
intak
limit
maximum
mg
per
kilogram
weight
day
regard
parenter
use
nativ
cyclodextrin
suffer
much
stronger
restrict
inde
ema
recommend
administr
directli
bloodstream
due
renal
toxic
addit
nativ
cd
known
caus
hemolysi
vitro
concentr
mm
respect
due
extract
phospholipid
cholesterol
erythrocyt
membran
nativ
cd
function
afford
larg
varieti
number
deriv
surpass
differ
molecul
accord
report
approv
human
use
field
pharmaceut
us
food
drug
administr
fda
list
approv
inert
materi
excipi
suit
oral
intraven
administr
use
topic
product
maxim
concentr
wv
fda
within
omethyl
cd
approv
statu
vari
one
molecul
next
instanc
trimeb
deem
unsaf
human
use
due
hemolyt
action
renal
toxic
sister
cyclodextrin
dimeb
also
featur
toxic
mostli
target
liver
dose
mgkg
mice
caus
elev
level
glutamatepyruv
transaminas
gpt
glutamateoxaloacet
transaminas
got
two
biomark
hepat
injuri
despit
dimeb
approv
fda
commerci
use
inject
vaccin
probabl
due
fact
present
low
amount
product
cyclodextrin
undergon
omethyl
random
posit
differ
safeti
profil
accord
differ
degre
substitut
rameb
randomli
methyl
betacyclodextrin
averag
methoxyl
group
per
glucos
unit
hydrolyt
action
erythrocyt
well
renal
toxic
higher
parent
reason
rameb
recommend
parenter
use
ema
crysmeb
name
fact
crystallin
solid
crystallin
methyl
betacyclodextrin
deliber
low
substitut
degre
averag
methyl
group
per
glucos
unit
ie
four
methyl
group
cd
molecul
design
high
biotoler
crysmeb
caus
hemolysi
alreadi
approv
dermal
applic
ingredi
cosmet
anoth
biocompat
cd
sulfobutyl
ether
develop
nonnephrotox
present
sever
fdaapprov
market
medic
oral
intraven
administr
cyclodextrin
mani
year
regard
excipi
solubil
stabil
properti
end
centuri
scientist
develop
concept
employ
cyclodextrin
medicin
compound
discoveri
part
research
new
polysulfatedbas
drug
candid
treat
hiv
human
immunodefici
viru
use
cyclodextrin
scaffold
sulfon
nativ
cyclodextrin
larg
number
hydroxyl
group
avail
allow
prepar
dozen
sulfon
deriv
vari
substitu
degre
substitut
sulfon
cd
shown
reduc
infect
hiv
stop
viral
replic
vitro
mechan
activ
shown
involv
inhibit
enzym
revers
transcriptas
inhibit
abil
hiv
fuse
target
cell
cyclodextrin
howev
never
market
hiv
therapi
may
part
associ
report
resist
sulfon
cd
hiv
first
year
identif
cholesterol
target
hiv
therapi
rekindl
interest
medicin
use
cyclodextrin
hiv
detail
follow
subsect
varieti
infecti
diseas
pathogen
depend
membran
cholesterol
intern
host
cell
mani
cyclodextrin
abl
bind
cholesterol
higher
sequest
abil
rameb
follow
dimeb
trimeb
determin
vitro
human
vascular
endotheli
cell
high
biocompat
make
typic
cyclodextrin
choic
medicin
applic
requir
cholesterol
sequest
abl
remov
cholesterol
molecul
membran
host
cell
render
less
suscept
viral
infect
also
remov
cholesterol
viral
particl
mechan
caus
disrupt
hiv
siv
simian
immunodefici
viru
abil
block
transmiss
viru
demonstr
studi
mice
vagin
applic
block
hiv
transmiss
mice
treat
get
infect
follow
hiv
exposur
furthermor
shown
reduc
inflammatori
respons
cultur
immun
cell
lower
product
interleukin
cytokin
encourag
result
vitro
mice
trigger
sever
research
project
aim
obtain
vaccin
hiv
base
next
obviou
step
studi
effect
anim
model
closer
human
rhesu
macaqu
anim
treat
intravagin
administr
subject
siv
contact
protect
infect
upon
first
contact
viru
howev
repeat
viral
inocul
week
later
also
treatment
led
largescal
infect
mean
test
dose
unsuit
vaccin
repeat
exposur
viru
studi
still
need
valid
medicin
applic
abil
cyclodextrin
sequest
cholesterol
allow
potenti
disrupt
viru
biomolecul
membran
membran
cholesterol
usual
locat
lipid
microdomain
call
lipid
raft
particl
influenza
viru
treat
rameb
cholesterol
deplet
figur
exhibit
disrupt
lipid
raft
consequ
structur
deform
viral
membran
microscopi
examin
allow
observ
hole
viral
envelop
furthermor
cholesterol
deplet
rameb
significantli
reduc
infect
viral
particl
influenza
strain
vitro
although
rameb
yet
regul
human
use
preliminari
result
open
way
applic
cyclodextrin
control
influenza
infect
human
abil
cyclodextrin
sequest
cholesterol
allow
potenti
disrupt
viru
biomolecul
membran
membran
cholesterol
usual
locat
lipid
microdomain
call
lipid
raft
particl
influenza
viru
treat
rameb
cholesterol
deplet
figur
exhibit
disrupt
lipid
raft
consequ
structur
deform
viral
membran
microscopi
examin
allow
observ
hole
viral
envelop
furthermor
cholesterol
deplet
rameb
significantli
reduc
infect
viral
particl
influenza
strain
vitro
although
rameb
yet
regul
human
use
preliminari
result
open
way
applic
cyclodextrin
control
influenza
infect
human
new
cyclodextrin
deriv
design
treatment
influenza
includ
famili
fullerenecyclodextrin
conjug
anoth
famili
pentacycl
triterpenefunction
per
deriv
terpen
deriv
potent
valu
low
viru
cultiv
insid
canin
epitheli
kidney
cell
mdck
line
mechan
action
bind
block
hemagglutinin
protein
viru
surfac
thu
prevent
interact
host
receptor
entri
viru
host
cell
new
cd
nontox
host
cell
seem
promis
new
molecul
antivir
action
data
still
limit
vitro
studi
research
need
conduct
molecul
fulli
understand
practic
util
antivir
properti
cyclodextrin
also
serv
base
develop
innov
influenza
vaccin
research
group
japan
vaccin
innov
use
nasal
deliveri
rout
afford
patientfriendli
administr
expect
better
accept
current
avail
inject
anoth
innov
aspect
vaccin
lie
presenc
adjuv
agent
activ
immunoglobulin
alreadi
approv
excipi
variou
oral
medicin
inject
one
chosen
excel
toler
synerg
effect
immunoglobulin
proven
sever
previou
vivo
studi
mice
macaqu
demonstr
bring
increas
product
antibodi
induc
product
subclass
immun
cell
respons
longterm
immun
memori
longterm
immun
viru
also
demonstr
effect
immun
occur
nasal
mucosa
site
administr
system
spread
throughout
entir
bodi
convey
strong
immun
viru
vaccin
undergo
phase
clinic
studi
start
octob
continu
present
day
success
first
new
cyclodextrin
deriv
design
treatment
influenza
includ
famili
fullerenecyclodextrin
conjug
anoth
famili
pentacycl
triterpenefunction
per
deriv
terpen
deriv
potent
ic
valu
low
viru
cultiv
insid
canin
epitheli
kidney
cell
mdck
line
mechan
action
bind
block
hemagglutinin
protein
viru
surfac
thu
prevent
interact
host
receptor
entri
viru
host
cell
new
cd
nontox
host
cell
seem
promis
new
molecul
antivir
action
data
still
limit
vitro
studi
research
need
conduct
molecul
fulli
understand
practic
util
antivir
properti
cyclodextrin
also
serv
base
develop
innov
influenza
vaccin
research
group
japan
vaccin
innov
use
nasal
deliveri
rout
afford
patientfriendli
administr
expect
better
accept
current
avail
inject
anoth
innov
aspect
vaccin
lie
presenc
adjuv
agent
activ
immunoglobulin
alreadi
approv
excipi
variou
oral
medicin
inject
one
chosen
excel
toler
synerg
effect
immunoglobulin
proven
sever
previou
vivo
studi
mice
macaqu
demonstr
bring
increas
product
antibodi
induc
product
subclass
immun
cell
respons
longterm
immun
memori
longterm
immun
viru
also
demonstr
effect
immun
occur
nasal
mucosa
site
administr
system
spread
throughout
entir
bodi
convey
strong
immun
viru
vaccin
undergo
phase
clinic
studi
start
octob
continu
present
day
success
first
cyclodextrinadjuv
vaccin
histori
deplet
cholesterol
rameb
viru
flavivirida
famili
shown
affect
flavivir
entri
target
cell
well
abil
replic
insid
cell
consid
promis
result
manag
infect
famili
includ
dengu
viru
den
japanes
enceph
viru
jev
dengu
fever
high
incid
tropic
subtrop
countri
object
sever
studi
concern
potenti
therapeut
applic
cyclodextrin
vitro
assay
monocyt
cell
model
myelomonocyt
cell
line
confirm
signific
reduct
infect
rate
upon
treatment
rameb
mm
associ
inabl
viral
particl
releas
genet
materi
infect
cell
importantli
rameb
interfer
viru
life
cycl
insid
carrier
asian
tiger
mosquito
aed
albopictu
mosquito
aed
aegypti
rameb
alter
protein
metabol
viru
insid
mosquito
cell
name
lower
express
nonstructur
protein
consid
protein
requir
viral
replic
excret
reduct
viral
secret
cultiv
mosquito
cell
treat
rameb
expect
howev
occur
investig
possibl
applic
rameb
prevent
dengu
transmiss
need
especi
studi
effect
mosquito
larva
success
new
methodolog
would
bring
innov
ecofriendli
method
environment
control
dengu
high
cholesterolbind
properti
rameb
led
research
investig
potenti
act
medicin
molecul
varieti
viral
agent
common
infect
viral
particl
cholesterol
exogen
part
particl
target
cd
abil
cd
reduc
viral
infect
alreadi
demonstr
sever
common
virus
like
human
metapneumoviru
hmpv
parainfluenza
viru
type
coronaviru
infecti
bronchiti
viru
ibv
herp
simplex
viru
even
less
common
one
newcastl
diseas
viru
ndv
andor
rameb
also
interfer
infect
virus
respons
chronic
infect
name
varicelazoost
viru
vzv
caus
chickenpox
hepat
c
viru
hcv
treatment
hepat
c
new
cyclodextrin
develop
base
fulleren
conjug
similar
way
cd
describ
influenza
treatment
conjug
fulleren
c
two
unit
design
combin
antivir
properti
c
good
aqueou
solubl
molecul
present
ic
hcv
describ
first
new
class
hcv
entri
inhibitor
leishmaniasi
neglect
tropic
diseas
endem
tropic
countri
central
south
america
africa
middl
east
threaten
spread
usa
south
europ
due
global
warm
combin
good
cholesterolsequest
abil
approv
use
inject
formul
excel
candid
leishmaniasi
therapi
balbc
mice
infect
parasit
leishmania
donovani
administr
aqueou
solut
ca
correspond
mgl
caus
reduct
liver
infect
compar
control
rameb
also
propos
new
leishmanicid
drug
studi
demonstr
effect
reduc
infect
l
donovani
abil
infect
immun
cell
host
also
patent
leishmanicid
use
rameb
dose
mgkg
bodi
weight
compris
varieti
administr
rout
includ
oral
inhal
implant
nevertheless
product
like
still
far
reach
market
sinc
toxic
rameb
fulli
elucid
cyclodextrin
regul
oral
administr
agenc
ema
fda
malaria
tropic
hemorrhag
fever
caus
protozoa
parasit
plasmodium
genu
clinic
challeng
diseas
due
increas
strain
resist
commonli
use
medic
chloroquin
search
new
medic
demonstr
anion
saccharid
effect
block
parasit
enter
target
cell
specif
erythrocyt
hepatocyt
base
find
anion
cyclodextrin
name
sulphat
substitu
prepar
test
antimalari
agent
cultur
plasmodium
falciparum
result
show
size
cyclodextrin
ring
critic
factor
activ
deriv
parent
cyclodextrin
inhibit
parasit
replic
potenc
activ
cyclodextrin
deriv
malaria
parasit
seem
mainli
relat
degre
substitut
inde
potent
compound
sodium
salt
polysulph
sulphat
group
per
cd
molecul
highest
averag
degre
sulphat
test
deriv
exhibit
ic
valu
p
falciparum
also
noteworthi
fact
cd
deriv
low
degre
sulphat
complet
inact
result
show
could
promis
new
lead
malaria
treatment
although
thorough
investig
safeti
profil
molecul
still
need
make
success
transit
clinic
applic
cryptosporidiosi
enter
infect
caus
parasit
speci
cryptosporirium
parvum
typic
manifest
wateri
diarrhea
strong
loss
liquid
greater
concern
babi
infant
pregnant
women
immunocompromis
patient
cryptosporidiosi
sever
infect
often
lead
death
hiv
coinfect
patient
diseas
transmit
water
contamin
oocyst
c
parvum
one
releas
four
infecti
sporozoit
insid
intestin
host
research
conduct
team
galicia
spain
begin
centuri
demonstr
two
nativ
cyclodextrin
use
control
criptosporidiosi
reduc
viabil
oocyst
treat
contamin
water
gl
h
allow
reduct
load
infect
mice
compar
mice
expos
amount
contamin
water
treat
administ
aqueou
suspens
infect
mice
also
show
cur
properti
treatment
rate
effect
given
h
infect
cryptosporidiosi
also
strong
impact
anim
farm
main
reservoir
c
parvum
anim
bovin
caprin
ovin
speci
cryptosporidiosi
caus
signific
econom
loss
breed
farm
anim
strong
demand
new
therapeut
mind
evalu
lamb
cryptosporidiosi
field
condit
singl
daili
dose
mgkg
bodi
weight
administ
three
consecut
day
shown
reduc
clinic
symptom
intens
infect
lamb
furthermor
prophylact
administr
within
h
birth
newborn
lamb
reduc
mortal
rate
number
infect
newborn
veterinari
applic
studi
newborn
goat
artifici
inocul
c
parvum
laboratorycontrol
condit
result
show
daili
dose
mgkg
bodi
weight
distribut
four
intak
six
consecut
day
abl
prevent
diarrhea
onset
case
five
six
goat
could
reduc
parasit
load
face
anim
consid
prone
interact
variou
compon
milk
serv
nourish
goat
kid
higher
dosag
perhap
prolong
treatment
time
would
worth
investig
determin
optim
therapeut
plan
studi
could
also
includ
clinic
trial
human
quit
safe
dietari
intak
limit
alreadi
use
nutraceut
beverag
scenario
cryptosporidiosiscaus
diarrhea
beverag
would
adequ
would
help
amelior
dehydr
infect
atherosclerosi
root
caus
heart
attack
stroke
peripher
vascular
diseas
patholog
arteri
wall
develop
progress
accumul
cholesterolrich
lipid
sensit
spot
arteri
form
plaqu
plaqu
oxid
cholesterol
thought
form
blockag
prevent
normal
mechan
organ
remov
lipid
buildup
discoveri
solubil
form
cholesterol
provid
new
hope
revert
accumul
atherosclerosi
plaqu
vivo
studi
mice
show
well
toler
daili
dose
mgday
four
week
afford
reduct
total
cholesterol
plasma
level
anoth
set
vivo
studi
mice
shown
although
plasma
cholesterol
alter
fight
atherosclerosi
help
dissolv
cholesterol
deposit
arteri
wall
reprogram
macrophag
metabol
cholesterol
solubl
oxysterol
excis
human
atherosclerot
carotid
plaqu
exhibit
antiinflammatori
action
regul
complementrel
gene
cell
plaqu
reduc
level
proinflammatori
molecul
complement
compon
role
cardiovascular
diseas
prevent
also
investig
given
alreadi
approv
nutrit
supplement
studi
conduct
group
healthi
volunt
focus
oral
administr
daili
dose
mg
week
signific
benefici
chang
profil
plasma
lipid
howev
observ
attribut
quasi
null
absorpt
oral
intak
note
also
effect
cyclodextrin
block
absorpt
dietari
lipid
measur
studi
wellknown
cholesterolbind
abil
serv
base
mode
action
rare
kidney
diseas
focal
segment
glomerulosclerosi
fsg
cholesterol
lipid
accumul
glomeruli
kidney
cell
respons
filtrat
becom
damag
leak
protein
urin
diseas
often
associ
hypoalbuminemia
hypertens
avail
medic
patient
frequent
requir
renal
transplant
remov
excess
cholesterol
kidney
restor
renal
function
albumin
level
bodi
homeostasi
use
treatment
fsg
success
complet
phase
clinic
studi
mice
approv
fda
april
phase
iia
trial
human
patient
niemannpick
diseas
npd
type
c
genet
neurodegen
disord
character
abnorm
accumul
cholesterol
sphingolipid
insid
lysosom
affect
cell
due
failur
gene
encod
transport
protein
respons
mobil
waterinsolubl
biomolecul
note
also
featur
distinguish
npd
type
c
type
b
associ
gene
encod
sphingomyelinas
affect
brain
cell
quit
strongli
trigger
sever
neurolog
symptom
ataxia
tremor
loss
muscl
tone
loss
vision
liver
spleen
may
also
affect
typic
display
enlarg
npd
higher
incid
children
caus
progress
loss
bodili
control
function
ultim
lead
death
lack
medic
npc
encourag
search
innov
medic
remov
lipid
deposit
brain
patient
obviou
choic
cholesterolsequest
properti
preliminari
studi
conduct
mous
model
intraven
administr
result
observ
conclud
unabl
cross
bloodbrain
barrier
order
abl
treat
npd
need
administ
invas
way
directli
spinal
canal
intrathec
administr
administr
intrathec
rout
show
posit
result
mous
cat
model
diseas
delay
progress
neurolog
damag
partial
recoveri
swell
brain
region
approv
orphan
drug
npd
type
c
fda
ema
sinc
use
intrathec
variou
clinic
trial
alreadi
end
one
trial
show
restor
neuron
cholesterol
homoeostasi
decreas
cn
patholog
children
less
month
age
three
children
age
month
improv
score
cognit
level
swallow
abil
fine
motor
skill
balancegait
anoth
trial
particip
wider
scale
age
year
confirm
overal
slow
progress
diseas
upon
intrathec
administr
dose
mgmonth
accord
toler
patient
patient
medic
three
year
mani
clinic
trial
still
ongo
start
phase
total
nine
current
activ
clinic
trial
engag
larg
number
varieti
medic
institut
around
globe
hope
help
elucid
role
longterm
toxicolog
safeti
biolog
fate
far
knowledg
limit
proteom
analysi
effect
cultur
fibroblast
donor
npd
type
c
show
increas
product
protein
involv
carri
lipid
cell
neuromuscular
block
agent
also
known
skelet
muscl
relax
molecul
abl
block
effect
acetylcholin
occupi
place
nicotin
receptor
striat
muscl
cell
commonli
use
surgic
procedur
relax
muscl
patient
ensur
immobil
facilit
insert
ventil
tube
trachea
surgic
procedur
finish
remov
neuromuscular
blockag
usual
done
administ
revers
agent
make
sure
patient
regain
control
muscular
function
quickli
possibl
artifici
ventil
remov
agent
usual
acetylcholinesteras
inhibitor
neostignim
lead
strong
increas
acetylcholin
level
high
concentr
acetylcholin
drive
replac
block
agent
nicotin
receptor
restor
normal
function
howev
classic
revers
drug
two
major
setback
select
caus
side
effect
muscarin
receptor
translat
dryness
mouth
gastrointestin
dysfunct
ii
spite
care
dose
revers
agent
residu
neuromuscular
blockag
common
issu
postop
patient
often
lead
respiratori
complic
innov
drug
neuromuscular
blockag
revers
thu
differ
mechan
action
avoid
issu
simpl
solut
use
cyclodextrin
remov
neuromuscular
block
agent
site
action
render
inact
entrap
caviti
rocuronium
bromid
one
use
drug
surgeri
requir
tracheal
intub
chosen
model
drug
deriv
design
maxim
inclus
affin
three
nativ
cd
best
suit
inner
diamet
includ
rocuronium
bromid
bulki
steroid
guest
new
deriv
call
sugammadex
obtain
perfunction
primari
hydroxyl
side
sulphanylpropano
acid
add
eight
linear
arm
base
structur
afford
strong
increas
caviti
depth
note
also
thiopropano
arm
sugammadex
present
anion
form
sodium
counterion
give
host
quit
uniqu
polar
figur
sodium
cation
highlight
purpl
sphere
function
group
substitu
highlight
red
sphere
oxygen
carboxyl
group
yellow
sphere
sulphur
atom
thioether
bond
remain
structur
repres
stick
red
color
oxygen
atom
grey
carbon
imag
redrawn
use
softwar
packag
mercuri
crystallograph
coordin
complex
avail
ccdc
refcod
idivog
sugammadex
form
stabl
complex
rocuronium
estim
everi
million
complex
avail
aqueou
medium
one
complex
dissoci
sugammadex
receiv
approv
new
drug
ema
fda
sugammadex
administr
intraven
dose
mgkg
bodi
weight
indic
revers
neuromuscular
blockag
induc
rocuronium
bromid
also
vecuronium
bromid
pancuronium
bromid
albeit
lower
affin
latter
case
time
need
sugammadex
revert
rocuroniuminduc
neuromuscular
blockad
much
shorter
ca
min
neostigmin
ca
min
caus
residu
neuromuscular
blockag
unless
cours
insuffici
dose
use
clearanc
bodi
also
occur
rapidli
within
h
done
kidney
practic
unalt
form
logic
attribut
strong
polar
good
aqueou
solubl
sugammadex
counterind
drug
also
associ
renal
clearanc
sugammadex
indic
use
patient
renal
failur
inclus
complex
may
fulli
elimin
even
seven
day
preserv
semen
freez
practic
costeffect
process
widespread
use
industri
poultri
cattl
also
preserv
lineag
hors
stallion
semen
usual
dilut
appropri
medium
may
egg
yolk
buffer
andor
glycerin
supplement
dilut
medium
cyclodextrin
studi
mammal
speci
seem
requir
cholesterol
along
cyclodextrin
poultri
cryopreserv
work
better
pure
cyclodextrin
use
sodium
cation
highlight
purpl
sphere
function
group
substitu
highlight
red
sphere
oxygen
carboxyl
group
yellow
sphere
sulphur
atom
thioether
bond
remain
structur
repres
stick
red
color
oxygen
atom
grey
carbon
imag
redrawn
use
softwar
packag
mercuri
crystallograph
coordin
complex
avail
ccdc
refcod
idivog
sugammadex
form
stabl
complex
rocuronium
estim
everi
million
complex
avail
aqueou
medium
one
complex
dissoci
sugammadex
receiv
approv
new
drug
ema
fda
sugammadex
administr
intraven
dose
mgkg
bodi
weight
indic
revers
neuromuscular
blockag
induc
rocuronium
bromid
also
vecuronium
bromid
pancuronium
bromid
albeit
lower
affin
latter
case
time
need
sugammadex
revert
rocuroniuminduc
neuromuscular
blockad
much
shorter
ca
min
neostigmin
ca
min
caus
residu
neuromuscular
blockag
unless
cours
insuffici
dose
use
clearanc
bodi
also
occur
rapidli
within
h
done
kidney
practic
unalt
form
logic
attribut
strong
polar
good
aqueou
solubl
sugammadex
counterind
drug
also
associ
renal
clearanc
sugammadex
indic
use
patient
renal
failur
inclus
complex
may
fulli
elimin
even
seven
day
preserv
semen
freez
practic
costeffect
process
widespread
use
industri
poultri
cattl
also
preserv
lineag
hors
stallion
semen
usual
dilut
appropri
medium
may
egg
yolk
buffer
andor
glycerin
supplement
dilut
medium
cyclodextrin
studi
mammal
speci
seem
requir
cholesterol
along
cyclodextrin
poultri
cryopreserv
work
better
pure
cyclodextrin
use
cryopreserv
stallion
semen
usual
employ
egg
yolk
dilut
success
replac
cholesterolload
complex
allow
cholesterol
convey
medium
watersolubl
manner
bring
extra
benefit
improv
semen
viabil
mobil
thaw
cryopreserv
goat
sperm
cyclodextrin
also
achiev
follow
similar
strategi
excess
amount
complex
ad
dilut
medium
sperm
prior
freez
object
let
cell
lose
less
membran
cholesterol
cryopreserv
process
reduct
membran
cholesterol
loss
confirm
fluoresc
microscopi
spermatozoa
better
endur
cold
shock
fertil
rate
still
increas
complex
also
use
cryopreserv
sperm
mammal
speci
name
markhoz
angora
buck
capra
hircu
buffalo
bull
boar
effect
ad
pure
rameb
mammalian
sperm
still
well
establish
rameb
addit
report
caus
dosedepend
deleteri
effect
mean
dose
must
care
ponder
instanc
ad
rameb
buffalo
sperm
dose
mgml
bring
dosedepend
increas
sperm
capacit
import
matur
step
requir
fertil
albeit
higher
dose
mgml
rameb
also
caus
loss
sperm
motil
thu
stress
need
casetocas
dose
adjust
moreov
bovin
sperm
rameb
supplement
caus
dosedepend
reduct
viabil
spermatozoa
less
viabl
control
ca
treat
mgml
mm
rameb
ca
treat
mgml
mm
rameb
chicken
sperm
preserv
ad
pure
rameb
benefit
sperm
motil
viabil
thaw
interestingli
ad
cholesterol
tandem
cyclodextrin
seem
detriment
chicken
sperm
supplement
complex
exhibit
reduc
motil
one
ad
exhibit
apoptosi
damag
acrosom
cell
wall
spermatozoa
corneal
blind
affect
around
million
peopl
origin
multifactori
includ
hyperkeratinis
associ
ophthalm
infect
small
eye
injuri
corneal
dystrophi
genet
origin
treatment
involv
replac
cornea
transplant
anoth
human
cornea
harvest
postmortem
volunt
organ
donor
besid
limit
associ
low
number
donor
allograft
corneal
transplant
prone
immun
reject
ideal
solut
would
produc
biomimet
artifici
cornea
adequ
transpar
mechan
resist
biocompat
cyclodextrin
help
bioengin
growth
collagen
vitro
make
structur
similar
one
found
cornea
collagen
fibril
cornea
particular
properti
narrow
fibril
connect
tissu
ensur
transpar
cyclodextrin
ad
collagen
fibrinogenesi
interact
hydrophob
amino
acid
residu
collagen
therebi
interrupt
crosslink
process
figur
transpar
mechan
robust
corneal
substitut
engin
use
nativ
cyclodextrin
modul
type
collagen
selfassembl
process
vitrif
ultrastructur
biomimet
corneal
substitut
similar
nativ
cornea
satur
test
use
cornea
also
show
resist
enough
support
reepithelialis
host
tissu
integr
materi
huge
potenti
biomimet
cornea
substitut
technolog
alreadi
protect
patent
although
precis
mode
inclus
known
cd
postul
interact
hydrophob
residu
amino
acid
present
singl
chain
format
amino
acid
chain
associ
trimer
trimer
subsequ
group
fibril
presenc
cyclodextrin
reduc
crosslink
variou
trimer
form
fibril
thu
lead
format
thin
fibril
type
collagen
use
cd
tissu
engin
applic
joint
bone
trauma
arthriti
current
develop
associ
collagen
instanc
help
form
new
bone
cartilag
incorpor
model
scaffold
made
collagen
glycoseaminoglycan
shown
influenc
metabol
activ
prolifer
mesenchym
stem
cell
drive
toward
osteochondr
differenti
happen
form
inclus
complex
two
growth
factor
releas
slow
sustain
fashion
joint
filler
compris
associ
hyaluron
chondroitin
patent
use
treatment
prevent
cartilag
degener
arthrosi
arthriti
diseas
fill
agent
soft
tissu
mucosa
present
review
describ
cyclodextrin
steadili
make
way
medicin
applic
api
biomed
engin
approv
medicin
cyclodextrin
includ
sugammadex
sugammadex
anion
deriv
design
revert
muscular
blockag
caus
rocuronium
bromid
sugammadex
includ
rocuronuim
bromid
high
specif
strong
affin
entrap
sugammadex
caviti
ensur
muscular
blockag
effect
quickli
termin
approv
orphan
drug
treatment
rare
kidney
diseas
focal
segment
glomerulosi
compassion
use
treatment
degen
brain
diseas
niemann
pick
diseas
type
c
two
diseas
pathophysiolog
involv
accumul
cholesterol
cell
live
tissu
action
thought
relat
abil
sequest
cholesterol
remov
damag
site
cholesterol
inclus
cd
deriv
open
way
variou
clinic
use
name
control
viral
infect
parasit
infect
malaria
leishmaniasi
although
precis
mode
inclus
known
cd
postul
interact
hydrophob
residu
amino
acid
present
singl
chain
format
amino
acid
chain
associ
trimer
trimer
subsequ
group
fibril
presenc
cyclodextrin
reduc
crosslink
variou
trimer
form
fibril
thu
lead
format
thin
fibril
type
collagen
use
cd
tissu
engin
applic
joint
bone
trauma
arthriti
current
develop
associ
collagen
instanc
help
form
new
bone
cartilag
incorpor
model
scaffold
made
collagen
glycoseaminoglycan
shown
influenc
metabol
activ
prolifer
mesenchym
stem
cell
drive
toward
osteochondr
differenti
happen
form
inclus
complex
two
growth
factor
releas
slow
sustain
fashion
joint
filler
compris
associ
hyaluron
chondroitin
patent
use
treatment
prevent
cartilag
degener
arthrosi
arthriti
diseas
fill
agent
soft
tissu
mucosa
present
review
describ
cyclodextrin
steadili
make
way
medicin
applic
api
biomed
engin
approv
medicin
cyclodextrin
includ
sugammadex
sugammadex
anion
deriv
design
revert
muscular
blockag
caus
rocuronium
bromid
sugammadex
includ
rocuronuim
bromid
high
specif
strong
affin
entrap
sugammadex
caviti
ensur
muscular
blockag
effect
quickli
termin
approv
orphan
drug
treatment
rare
kidney
diseas
focal
segment
glomerulosi
compassion
use
treatment
degen
brain
diseas
niemann
pick
diseas
type
c
two
diseas
pathophysiolog
involv
accumul
cholesterol
cell
live
tissu
action
thought
relat
abil
sequest
cholesterol
remov
damag
site
cholesterol
inclus
cd
deriv
open
way
variou
clinic
use
name
control
viral
infect
parasit
infect
malaria
leishmaniasi
criptosporidiasi
use
cd
remov
cholesterol
lipid
build
arteri
atherosclerosi
plaqu
also
studi
interest
preliminari
result
studi
need
confirm
util
cd
manag
cardiovascular
diseas
atherosclerosi
develop
complex
process
reason
activ
cd
expect
limit
cholesterol
lipid
necessari
investig
possibl
interact
cd
inflamm
signal
molecul
immun
cell
occur
site
atherosclerosi
plaqu
macrophag
cyclodextrin
also
interact
collagen
make
promis
modul
medicin
biomateri
develop
biomimet
cornea
prepar
grow
collagen
cdcontain
medium
well
fill
materi
arthritisdamag
joint
made
cd
associ
collagen
glycosaminoglycan
exampl
present
review
earli
stage
new
era
medicin
cyclodextrin
excel
biocompat
cd
wide
rang
possibl
interact
biomolecul
flexibl
function
obtain
deriv
interact
specif
select
biomolecular
target
give
vast
medicin
potenti
mani
applic
expect
aris
near
futur
fund
thank
due
univers
aveiro
fctmec
para
e
tecnologia
da
e
da
nation
fund
applic
cofinanc
feder
european
fund
region
develop
within
partnership
agreement
gener
financi
support
project
refer
fct
randomli
methyl
siv
simian
immunodefici
viru
trimeb
tumour
necrosi
factor
alpha
homo
sapien
pleural
myelomonocyt
cell
line
vzv
varicelazoost
viru
chickenpox
viru
world
health
organis
transform
growth
factor
beta
cytokin
famili
